Immunotherapy
-
healthJohnson & Johnson CEO Predicts Cancer Cures Within Next Decade
J&J Chairman Joaquin Duato outlines a realistic ten-year timeline for curing specific cancers and converting others into manageable chronic conditions through immunotherapy and AI.
-
healthLung Cancer Resistance Tied to Cell Reprogramming via TP53
New research links lung adenocarcinoma plasticity and treatment resistance to TP53-driven developmental reprogramming, activating branching morphogenesis as a key marker.
-
healthGut Microbiome Function Key to Unlocking Cancer Therapy Response, ESCMID 2026 Reveals
ESCMID 2026 highlights the gut microbiome's functional role in modulating cancer immunotherapy and chemotherapy responses, moving beyond bacterial taxonomy.
-
healthSteroids Linked to Shorter Survival in Immunotherapy Patients
Study finds systemic glucocorticoids near ICI initiation may reduce overall survival in cancer patients, urging cautious steroid use.
-
healthDeep Learning Outperforms Radiomics in Predicting Immunotherapy Outcomes in NSCLC
Deep learning models show superior accuracy over radiomics in predicting immunotherapy outcomes for metastatic NSCLC, promising better treatment personalization.
-
healthOnc Now: The Challenge of Translating Early-Phase Cancer Research
Dr. Victor Moreno Garcia discusses why many promising cancer therapies fail in Phase I-III trials and the role of AI.
-
healthAsthma Drug Shows Promise Against Hard-to-Treat Cancers
Montelukast, a common asthma drug, may help fight triple-negative breast cancer by reprogramming immune cells to attack tumors.
-
healthImmunotherapy Shows Promise for Treatment-Resistant Depression
A small early trial suggests tocilizumab, an anti-inflammatory drug, may help those with depression not responding to standard antidepressants.